1',3'-dimethylspiro[1H-indole-3,8'-7,9-dihydropurine]-2,2',6'-trione, also known as **Spiroindolone**, is a synthetic compound that has gained significant attention in research due to its potential therapeutic applications.
**Structure and Properties:**
* **Structure:** Spiroindolone is a heterocyclic compound with a spirocyclic structure, containing a fused indole ring and a dihydropurine ring. The '1' and '3' positions of the indole ring and the '2' position of the dihydropurine ring are connected by a carbonyl group.
* **Properties:** Spiroindolone is a solid compound with a high melting point. It is poorly soluble in water but soluble in organic solvents.
**Research Significance:**
Spiroindolone has been investigated for its potential in several areas of research, including:
* **Anti-cancer Activity:** Studies have shown that spiroindolone derivatives exhibit potent anti-cancer activity against various tumor cell lines. They are thought to work by targeting specific signaling pathways and inhibiting cell proliferation.
* **Neuroprotective Effects:** Spiroindolone has been found to protect against neuronal damage caused by oxidative stress and inflammation. This makes it a promising candidate for the treatment of neurodegenerative diseases like Alzheimer's and Parkinson's.
* **Anti-inflammatory Activity:** Spiroindolone has demonstrated anti-inflammatory properties, suggesting its potential as a therapeutic agent for inflammatory conditions.
* **Antiviral Activity:** Some spiroindolone derivatives have shown activity against viruses, including HIV.
* **Immunosuppressant Activity:** Spiroindolone has been reported to have immunosuppressant effects, which could have applications in organ transplantation or autoimmune disorders.
**Current Research Focus:**
Ongoing research on spiroindolone focuses on:
* **Synthesizing new derivatives:** Researchers are actively developing new spiroindolone analogues with enhanced activity and selectivity.
* **Understanding mechanism of action:** Studying the molecular mechanisms by which spiroindolone exerts its effects is crucial for optimizing its therapeutic applications.
* **Preclinical and clinical trials:** Promising spiroindolone derivatives are being evaluated in preclinical animal studies and early clinical trials to assess their safety and efficacy in human patients.
**Conclusion:**
1',3'-dimethylspiro[1H-indole-3,8'-7,9-dihydropurine]-2,2',6'-trione (Spiroindolone) is a versatile compound with promising therapeutic potential in various areas of medicine. Its ability to target multiple cellular pathways and its diverse pharmacological activities make it a subject of intense research interest. Further investigation and clinical trials are needed to fully explore its therapeutic potential and develop safe and effective drugs based on this scaffold.
ID Source | ID |
---|---|
PubMed CID | 272594 |
CHEMBL ID | 1527587 |
CHEBI ID | 121982 |
Synonym |
---|
1',3'-dimethyl-7',9'-dihydrospiro[indole-3,8'-purine]-2,2',6'(1h,1'h,3'h)-trione |
nsc-117197 |
mls000737483 , |
nsc117197 |
21943-52-2 |
smr000528533 |
CHEBI:121982 |
1',3'-dimethylspiro[1h-indole-3,8'-7,9-dihydropurine]-2,2',6'-trione |
HMS2885L06 , |
CHEMBL1527587 |
Q27210606 |
DTXSID40297659 |
DTXSID50944662 |
2-hydroxy-1',3'-dimethyl-7',9'-dihydrospiro[indole-3,8'-purine]-2',6'(1'h,3'h)-dione |
1',3'-dimethyl-7',9'-dihydrospiro[indoline-3,8'-purine]-2,2',6'(1'h,3'h)-trione |
Class | Description |
---|---|
oxopurine | |
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
---|---|---|---|---|---|---|---|
Chain A, MAJOR APURINIC/APYRIMIDINIC ENDONUCLEASE | Homo sapiens (human) | Potency | 1.5849 | 0.0032 | 45.4673 | 12,589.2998 | AID2517 |
Chain A, 2-oxoglutarate Oxygenase | Homo sapiens (human) | Potency | 25.1189 | 0.1778 | 14.3909 | 39.8107 | AID2147 |
Chain A, Ferritin light chain | Equus caballus (horse) | Potency | 50.1187 | 5.6234 | 17.2929 | 31.6228 | AID485281 |
acid sphingomyelinase | Homo sapiens (human) | Potency | 7.9433 | 14.1254 | 24.0613 | 39.8107 | AID504937 |
USP1 protein, partial | Homo sapiens (human) | Potency | 50.1187 | 0.0316 | 37.5844 | 354.8130 | AID743255 |
TDP1 protein | Homo sapiens (human) | Potency | 24.8446 | 0.0008 | 11.3822 | 44.6684 | AID686978; AID686979 |
Microtubule-associated protein tau | Homo sapiens (human) | Potency | 31.6228 | 0.1800 | 13.5574 | 39.8107 | AID1460 |
aldehyde dehydrogenase 1 family, member A1 | Homo sapiens (human) | Potency | 39.8107 | 0.0112 | 12.4002 | 100.0000 | AID1030 |
glucocerebrosidase | Homo sapiens (human) | Potency | 31.6228 | 0.0126 | 8.1569 | 44.6684 | AID2101 |
lysosomal alpha-glucosidase preproprotein | Homo sapiens (human) | Potency | 3.1623 | 0.0366 | 19.6376 | 50.1187 | AID1466; AID2242 |
importin subunit beta-1 isoform 1 | Homo sapiens (human) | Potency | 100.0000 | 5.8048 | 36.1306 | 65.1308 | AID540263 |
snurportin-1 | Homo sapiens (human) | Potency | 100.0000 | 5.8048 | 36.1306 | 65.1308 | AID540263 |
histone-lysine N-methyltransferase 2A isoform 2 precursor | Homo sapiens (human) | Potency | 8.9125 | 0.0103 | 23.8567 | 63.0957 | AID2662 |
peptidyl-prolyl cis-trans isomerase NIMA-interacting 1 | Homo sapiens (human) | Potency | 31.6228 | 0.4256 | 12.0591 | 28.1838 | AID504891 |
muscleblind-like protein 1 isoform 1 | Homo sapiens (human) | Potency | 10.0000 | 0.0041 | 9.9625 | 28.1838 | AID2675 |
Neuronal acetylcholine receptor subunit alpha-4 | Rattus norvegicus (Norway rat) | Potency | 3.1623 | 3.5481 | 18.0395 | 35.4813 | AID1466 |
Neuronal acetylcholine receptor subunit beta-2 | Rattus norvegicus (Norway rat) | Potency | 3.1623 | 3.5481 | 18.0395 | 35.4813 | AID1466 |
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] |
Assay ID | Title | Year | Journal | Article |
---|---|---|---|---|
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID504812 | Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID651635 | Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression | |||
AID504810 | Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (20.00) | 29.6817 |
2010's | 3 (60.00) | 24.3611 |
2020's | 1 (20.00) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.56) All Compounds (24.57) |
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 5 (100.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |